Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
Background Immunocompromised individuals are not optimally protected by COVID-19
vaccines and potentially require additional preventive interventions to mitigate the risk of …
vaccines and potentially require additional preventive interventions to mitigate the risk of …
The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future
A Antinori, M Bausch-Jurken - The Journal of Infectious …, 2023 - academic.oup.com
Approximately 3% of US adults are immunocompromised and less capable of fighting
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …
[HTML][HTML] Disparities in COVID-19 mortality amongst the immunosuppressed: A systematic review and meta-analysis for enhanced disease surveillance
M Leston, W Elson, JM Ordóñez-Mena, D Kar… - Journal of Infection, 2024 - Elsevier
Background Effective disease surveillance, including that for COVID-19, is compromised
without a standardised method for categorising the immunosuppressed as a clinical risk …
without a standardised method for categorising the immunosuppressed as a clinical risk …
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
Y Cai, S Diallo, K Rosenthal, K Ren, DJ Flores… - Science Translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
There is a public health need to understand how different frequencies of COVID-19 booster
vaccines may mitigate the risk of severe COVID-19, while accounting for waning of …
vaccines may mitigate the risk of severe COVID-19, while accounting for waning of …
Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study
M Lahouati, C Cazanave, A Labadie, P Gohier… - Scientific Reports, 2023 - nature.com
The aim of this study was to describe the outcomes of targeted COVID-19 treatments in
immunocompromised patients with asymptomatic or mild COVID-19 during the period of …
immunocompromised patients with asymptomatic or mild COVID-19 during the period of …
Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and …
A Ketkar, V Willey, L Glasser, C Dobie, C Wenziger… - Advances in …, 2024 - Springer
Abstract Introduction/Methods EPOCH-US is an ongoing, retrospective, observational cohort
study among individuals identified in the Healthcare Integrated Research Database …
study among individuals identified in the Healthcare Integrated Research Database …
The Short and Long of COVID-19: A Review of Acute and Chronic Radiologic Pulmonary Manifestations of SARS-2-CoV and Their Clinical Significance
S Simpson, M Hershman… - Clinics in Chest …, 2024 - chestmed.theclinics.com
The Short and Long of COVID-19 - Clinics in Chest Medicine Skip to Main Content Skip to Main
Menu Advertisement Clinics in Chest Medicine Log in Register Log in Subscribe Claim Cart (1 …
Menu Advertisement Clinics in Chest Medicine Log in Register Log in Subscribe Claim Cart (1 …
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) …
ABSTRACT AZD7442 is a combination of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)-neutralizing antibodies, tixagevimab and cilgavimab, developed for pre …
(SARS-CoV-2)-neutralizing antibodies, tixagevimab and cilgavimab, developed for pre …
Mucosal adenoviral-vectored vaccine boosting durably prevents XBB. 1.16 Infection in Nonhuman Primates
M Gagne, BJ Flynn, SF Andrew, DR Flebbe… - BioRxiv, 2023 - biorxiv.org
Waning immunity and continued virus evolution have limited the durability of protection from
symptomatic infection mediated by intramuscularly (IM)-delivered mRNA vaccines against …
symptomatic infection mediated by intramuscularly (IM)-delivered mRNA vaccines against …